Micafungin sodium and Malignant neoplasm progression - a phase IV clinical study of FDA data

Summary:

Malignant neoplasm progression is reported as a side effect among people who take Micafungin sodium (micafungin sodium), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Meropenem, and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Malignant neoplasm progression when taking Micafungin sodium. It is created by eHealthMe based on reports of 1,784 people who have side effects when taking Micafungin sodium from the FDA, and is updated regularly.

What is Micafungin sodium?

Micafungin sodium has active ingredients of micafungin sodium. eHealthMe is studying from 1,787 Micafungin sodium users. Check the latest studies of Micafungin sodium.

What is Malignant neoplasm progression?

Malignant neoplasm progression (cancer tumour came back) is found to be associated with 1,515 drugs and 1,634 conditions by eHealthMe. Check the latest studies of Malignant neoplasm progression.

On Jul, 07, 2026

1,784 people reported to have side effects when taking Micafungin sodium.
Among them, 17 people (0.95%) have Malignant neoplasm progression.

Could Micafungin sodium cause Malignant neoplasm progression?

Among these 17 people:

How long have people been on Micafungin sodium when they have Malignant neoplasm progression? *

What is the gender of people who have Malignant neoplasm progression when taking Micafungin sodium? *

female: 25 %
male: 75 %

What is the age of people who have Malignant neoplasm progression when taking Micafungin sodium? *

What are other drugs people take besides Micafungin sodium? *

Meropenem: 6 people, 35.29%
Fludarabine Phosphate: 5 people, 29.41%
Methylprednisolone: 4 people, 23.53%
Sprycel: 4 people, 23.53%
Metoclopramide Hcl: 4 people, 23.53%
Sulfamethoprim: 3 people, 17.65%
Cytarabine: 3 people, 17.65%
Cefepime Hydrochloride: 3 people, 17.65%
Voriconazole: 3 people, 17.65%
Methotrexate: 3 people, 17.65%

What are other side effects people have besides Malignant neoplasm progression? *

White Blood Cell Count Decreased: 7 people, 41.18%
Thrombocytopenia (decrease of platelets in blood): 6 people, 35.29%
Fever: 4 people, 23.53%
Pneumonia: 4 people, 23.53%
Fibrin Degradation Products Increased: 3 people, 17.65%
Pulmonary Haemorrhage (acute bleeding from the lung): 3 people, 17.65%
Infection: 3 people, 17.65%
Fibrin Increased: 3 people, 17.65%
Fibrin D Dimer Increased: 3 people, 17.65%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 3 people, 17.65%

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 3 people, 17.65%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 11.76%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 11.76%
Bone Marrow Conditioning Regimen: 2 people, 11.76%
Pyogenic Liver Abscess (liver abscess caused by bacteria): 1 person, 5.88%
Diarrhea: 1 person, 5.88%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 5.88%
Adrenoleukodystrophy (loss of myelin surrounding nerve cells in the brain and progressive adrenal gland): 1 person, 5.88%
Anaemia (lack of blood): 1 person, 5.88%
Carcinoid Tumor: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Micafungin sodium and have Malignant neoplasm progression?

- Check whether Malignant neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Micafungin sodium:

Micafungin sodium (1,787 reports)

Browse all side effects of Micafungin sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,515 drugs)

Browse all the conditions that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,634 conditions)

Related publications that referenced our studies

Cheng HI, Chen TH, Chung TC, Lee HY, Yu CY, "Micafungin-Induced Hyperbilirubinemia: A Case Report", 臺灣臨床藥學雜誌, 2014 Jun .
Cheng HI, Chen TH, Chung TC, Lee HY, Yu CY, "Micafungin-Induced Hyperbilirubinemia: A Case Report", 臺灣臨床藥學雜誌, 2014 Jun .

How the study uses the data?

The study uses data from the FDA. It is based on micafungin sodium (the active ingredients of Micafungin sodium) and Micafungin sodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.